Rubicon Research Limited has launched its initial public offering (IPO), marking a key development in India’s pharmaceutical and research services sector. The IPO is a book-built issue of ₹1,377.50 crore, consisting of a fresh issue of 1.03 crore shares aggregating ₹500 crore and an offer for sale of 1.81 crore shares aggregating ₹877.50 crore. This structure provides a unique opportunity for investors to participate both in the expansion of the company through fresh capital and in acquiring shares from existing shareholders.

IPO Overview

The Rubicon Research IPO opened for subscription on October 9, 2025, and will remain open until October 13, 2025. The allotment of shares is expected to be finalized on October 14, 2025, with listing on BSE and NSE tentatively scheduled for October 16, 2025. This structured timeline allows investors to plan their participation effectively.

The price band for the IPO is fixed between ₹461 and ₹485 per share, and the lot size for retail investors is 30 shares, requiring a minimum investment of ₹14,550 at the upper price band. For small and medium institutional investors (sNII), the lot size is 14 lots, i.e., 420 shares amounting to ₹2,03,700, while for big institutional investors (bNII), the lot size is 69 lots, equivalent to 2,070 shares or ₹10,03,950.

About Rubicon Research Limited

Rubicon Research is a prominent contract research and pharmaceutical services company, providing end-to-end research solutions to global pharmaceutical companies. The firm focuses on drug discovery, development, and clinical research, supporting innovation across therapeutic segments and regulatory environments.

Key highlights of Rubicon Research include:

• Comprehensive Research Services: Offers services spanning drug discovery, formulation development, clinical trials, regulatory support, and pharmacovigilance.

• Global Client Base: Works with leading international pharmaceutical and biotech companies, enabling cross-border collaboration and adherence to global standards.

• Innovation & Technology: Leverages advanced AI-driven analytics, data integration, and modern laboratory practices to deliver high-quality research outcomes.

IPO Structure and Investment Details

The Rubicon Research IPO is structured as a combination of fresh issue and offer for sale:

1. Fresh Issue (₹500 crore): Funds raised through this portion will support expansion of research capabilities, infrastructure development, and strategic initiatives for business growth.

2. Offer for Sale (₹877.50 crore): Existing shareholders sell their stake, providing liquidity and enabling new investors to participate in the company’s ownership.

Investment details for various categories:

• Retail Individual Investors (RII):

  • Lot size: 30 shares

  • Minimum investment: ₹14,550 at the upper price band

• Small and Medium Institutional Investors (sNII):

  • Lot size: 14 lots (420 shares)

  • Investment: ₹2,03,700

• Big Institutional Investors (bNII):

  • Lot size: 69 lots (2,070 shares)

  • Investment: ₹10,03,950

Investors are advised to consider their financial capacity and risk appetite before subscribing.

Bidding and Allotment Process

Rubicon Research IPO follows the book-building method, allowing investors to bid within the price band.

• Bidding Window: October 9-13, 2025

• Allotment Date: October 14, 2025

• Listing Date: Tentatively October 16, 2025 on BSE and NSE

In case of oversubscription, the allotment will be made proportionately to investors in each category. Retail investors typically receive proportionate allocation to ensure fair participation.

Significance of the IPO

The Rubicon Research IPO is significant due to several reasons:

1. Funding Growth: The fresh issue will enable Rubicon Research to expand research facilities, hire talent, and strengthen global operations.

2. Market Liquidity: The offer for sale provides liquidity to existing shareholders and introduces new investors to the company.

3. Investor Access: Allows both retail and institutional investors to participate in a high-growth, research-driven company with global clientele.

4. Sector Visibility: Enhances awareness and investor interest in India’s contract research and pharmaceutical services sector, which is growing rapidly in the global market.

Risks and Considerations for Investors

While the IPO presents an exciting opportunity, investors should note potential risks:

• Market Volatility: Equity prices fluctuate and the IPO listing price may vary from the issue price.

• Sector-Specific Risks: Pharmaceutical research and clinical services are subject to regulatory approvals, clinical trial outcomes, and global competition.

• Liquidity Risk: Initial trading may witness price volatility based on demand-supply dynamics.

• Regulatory Changes: Any modification in SEBI, FDA, or other regulatory frameworks could impact operations.

Investors should read the IPO prospectus carefully and assess alignment with their investment objectives.

How to Apply for Rubicon Research IPO

Applications can be submitted through:

1. Online Platforms: Brokers, banks, and BSE/NSE online portals.

2. Physical Applications: Submitted via designated brokers and registrars, though online channels are more common.

3. UPI-Based Payment: Retail investors can use UPI payments for seamless and fast transaction processing.

Applications must be submitted before the closing date (October 13, 2025) to ensure participation.

Market Outlook and Timing

The Rubicon Research IPO is well-timed amid increasing investor interest in pharmaceutical research and technology-driven healthcare services. With India emerging as a global hub for clinical research and drug development, this IPO offers a strategic entry point for long-term investors.

The price band of ₹461-₹485 is attractive, especially for retail investors seeking exposure to a growing, high-margin industry. Market analysts anticipate strong subscription levels, with potential for listing gains depending on demand and broader market conditions.

Conclusion

Rubicon Research Limited’s IPO, valued at ₹1,377.50 crore, provides a rare opportunity for investors to participate in a leading Indian research and pharmaceutical services company. With a combination of fresh issue and offer for sale, investors can support the company’s growth while gaining access to a high-potential sector.

With subscription open from October 9-13, 2025, allotment on October 14, and tentative listing on October 16, 2025, investors have a clear timeline to plan their participation. By evaluating their risk tolerance and investment goals, investors can make informed decisions to subscribe to this strategically significant IPO.

The Rubicon Research IPO not only represents an investment opportunity but also showcases India’s growing capabilities in contract research, pharmaceutical innovation, and global service delivery, positioning it as a high-growth sector for domestic and international investors.

Join our Telegram Channel for Latest News and Regular Updates.

Start your Mutual Fund Journey  by Opening Free Account in Asset Plus.

Start your Stock Market Journey and Apply in IPO by Opening Free Demat Account in Choice Broking FinX.